Skip Navigation Change Font Size

Audit (A-09-11-01011)

07-26-2012
Syntrix Biosystems, Inc.'s Costs Claimed Under the Recovery Act for National Institutes of Health Grant 3R44CA094612-05S2 Were Unallowable

Executive Summary

Of the $200,000 of costs that Syntrix Biosystems, Inc., claimed against the Recovery Act grant, the entire amount was unallowable.

Complete Report

Download the complete report

Adobe® Acrobat® is required to read PDF files.

I'm Looking For

Let's start by choosing a topic

Exclusions Database Report Fraud
Newsletter Sign Up Envelop Graphic

Stay up to date on the latest OIG news and opinions

Office of Inspector General, U.S. Department of Health and Human Services | 330 Independence Avenue, SW, Washington, DC 20201